Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia intends to issue convertible to replace current convertible loan

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) intends to issue a new convertible loan to replace the convertible loan (2016:1) in the total nominal amount SEK 28 million, which m...
Read more

Interim report for the period May 2016 – January 2017

Oasmia Pharmaceutical AB (publ) Interim report for the period May 2016 – January 2017 Strategic changes within Animal Health Division
Read more

Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors

Uppsala, Sweden March 1st, 2017 – Chairman Anders Lönner of Oasmia Pharmaceutical AB (NASDAQ: OASM) has announced his withdrawal from the board of directors, a decision that has raised numerous que...
Read more
To news archive